Ortin Global Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Ortin Global Ltd is ₹ 14.5 as of 29 Apr 15:30 . The P/E Ratio of Ortin Global Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Ortin Global Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Ortin Global Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Ortin Global Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Ortin Global Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Ortin Global Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Ortin Global Ltd

Ortin Laboratories Limited was incorporated in October, 1986 with a nominal capital of Rs 1 lakh to offer quality Drugs and Medicines to the suffering mankind.
The Company is a leading and predominant Pharmaceutical Manufacturer of Drugs and Medicines in India.
The company is engaged in manufacture of Pharma formulations.
They manufacture a range of pharmaceutical formulations of tablets, capsules, syrups, dry powders, and ointments in India.
The company is having their manufacturing unit at Medak in Andhra Pradesh, which is equipped with technically modern manufacturing facilities to produce complete range of Pharmaceutical Formulations. The company offer anti arthritic drugs, antibiotics, chemo therapeutics, analgesics and antipyretics, cardiac and cardio vascular drugs, anti diarroheal drugs, anti depressants, anti hypertensive, anti aids, anti tuberculosis drugs, gynaecological drugs, antibiotics, anti diabetic, antacids anti ulcer drugs, anti allergics, anti-cold, decongestants, antioxidents, vitamins, minerals, anti bacterial drugs, anti emetics, anti helmenthetics, nutritional supplements and protein, and appetizers.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Ortin Global Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Ortin Global Ltd or Sanofi India Ltd?

Market cap of Ortin Global Ltd is 12 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Ortin Global Ltd and Sanofi India Ltd?

The stock performance of Ortin Global Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ortin Global Ltd and Sanofi India Ltd?

As of May 3, 2026, the Ortin Global Ltd stock price is INR ₹15.5. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Ortin Global Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Ortin Global Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.